Platelet and vessel associated prostacyclin and thromboxane A2/prostaglandin endoperoxide receptors.
Synthetic stable analogues of thromboxane A2 (TXA2), cyclic endoperoxides (PGH2) and prostacyclin (PGI2) opened up new opportunities for investigating the mechanisms of action of these compounds. They proved to be useful pharmacological probes for characterizing PGI2 and TXA2/PGH2 receptors. Over the past few years, new synthetic antagonists with high specificity allowed the modulation of biological responses to endogenous eicosanoids. These compounds will, therefore, considerably promote our understanding of the biological function and significance of arachidonate metabolites. The present review summarizes current concepts that have arisen concerning platelet and vascular PGI2 and TXA2/PGH2 receptors, their transmembrane signal transduction, as well as their possible implications in the pathophysiology of cardiovascular disease.
D000262:Adenylyl Cyclases / Q000378:metabolism; D001792:Blood Platelets / Q000502:physiology* / Q000503:physiopathology; D002118:Calcium / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology / Q000503:physiopathology; D000242:Cyclic AMP / Q000502:physiology; D011464:Epoprostenol / Q000502:physiology*; D006801:Humans; D006868:Hydrolysis; D007473:Ion Channels / Q000378:metabolism; D009131:Muscle, Smooth, Vascular / Q000502:physiology*; D010716:Phosphatidylinositols / Q000378:metabolism; D044006:Receptors, Epoprostenol; D011982:Receptors, Prostaglandin / Q000037:antagonists & inhibitors / Q000502:physiology*; D017482:Receptors, Thromboxane; D013931:Thromboxanes / Q000037:antagonists & inhibitors / Q000502:physiology*
D007473:Ion Channels; D010716:Phosphatidylinositols; D044006:Receptors, Epoprostenol; D011982:Receptors, Prostaglandin; D017482:Receptors, Thromboxane; D013931:Thromboxanes; C055662:prostaglandin endoperoxide receptor; D011464:Epoprostenol; D000242:Cyclic AMP; D000262:Adenylyl Cyclases; D002118:Calcium